Art

J-GLOBAL ID：202002218862182756   Reference number：20A0282481

Promising Treatment for Type 2 Diabetes: Fecal Microbiota Transplantation Reverses Insulin Resistance and Impaired Islets

2型糖尿病の有望な治療: 糞便Microbiota移植はインスリン抵抗性と膵島障害を逆転させる【JST・京大機械翻訳】

Author (11)： Wang Hui (Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China) ,  Lu Yuan (Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China) ,  Yan Yan (Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China) ,  Tian Shanshan (Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China) ,  Zheng Dongjie (Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China) ,  Leng Dongjing (Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China) ,  Wang Cao (Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China) ,  Jiao Jingfeng (Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China) ,  Wang Zhiguo (Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China) ,  Bai Yunlong (Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China) ,  Bai Yunlong (Translational Medicine Research and Cooperation Center of Northern China, Chronic Disease Research Institute, Heilongjiang Academy of Medical Sciences, Harbin, China)
Material： Frontiers in Cellular and Infection Microbiology (Web)
Volume： 9  Page： 455  Publication year： 2019 
JST Material Number： U7063A  ISSN： 2235-2988  Document type： Article
Article type： 原著論文  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： Type 2 diabetes is a common me...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A0282481&from=J-GLOBAL&jstjournalNo=U7063A") }}

Thesaurus term： apoptosis ,  *diabetes mellitus ,  *Langerhans islet ,  immunohistochemistry ,  *insulin ,  *type 2 diabetes mellitus ,  microflora ,  HbA1c ,  enteric microbe ,  therapeutic planning ,  inflammation ,  energy metabolism ,  *insulin resistance ,  flow cytometry ,  immunological reaction

Author keywords (5)： diabetic ,  microbiota ,  FMT ,  apoptosis ,  inflammation

JST classification (1)： Physiology and pathogenicity of microbial infection  (EG03053T)

Reference (33)：

• Aron-Wisnewsky J., Clement K., Nieuwdorp M. (2019). Fecal microbiota transplantation: a future therapeutic option for Obesity/Diabetes? Curr. Diab. Rep. 19:51. doi: 10.1007/s11892-019-1180-z
• Aydin O., Nieuwdorp M., Gerdes V. (2018). The gut microbiome as a target for the treatment of Type 2 Diabetes. Curr. Diab. Rep. 18:55. doi: 10.1007/s11892-018-1020-6
• Borody T. J., George L., Andrews P., Brandl S., Moore-Jones D. (1989). Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med. J. Aust. 150:604. doi: 10.5694/j.1326-5377.1989.tb136704.x
• Burrello C., Garavaglia F., Cribiu F. M., Ercoli G., Lopez G., Troisi J., et al. (2018). Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells. Nat. Commun. 9:5184. doi: 10.1038/s41467-018-07359-8
• Butler A. E., Janson J., Bonner-Weir S., Ritzel R., Rizza R. A., Butler P. C. (2003). β-Cell deficit and increased β-cell apoptosis in humans with Type 2 Diabetes. Diabetes 52, 102-110. doi: 10.2337/diabetes.52.1.102

Terms in the title (9)： 2型糖尿病 ,  治療 ,  糞便 ,  Microbiota ,  移植 ,  インスリン抵抗性 ,  膵島 ,  障害 ,  逆転